Trading

Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study

Summary

Lexeo Therapeutics has shared encouraging interim data from an early-stage clinical trial assessing its gene therapy for a specific inherited heart condition. The treatment significantly lowered the arrhythmia burden in trial participants. The company now intends to initiate a pivotal study for the therapy in the future.

Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) and outlined plans to launch a pivotal study in late 2027. PKP2-ACM is an inherited heart muscle condition caused by a change, or variant, in the PKP2 gene. The clinical-stage genetic medicine company dosed 10 participants,…

Source: Read the full story at Top Stories Feed

Follow Tech & Money Press for daily watchlists and market news

XFacebookInstagramTikTokYouTube
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.
About UsContactPrivacy PolicyDisclaimer
Not financial advice. Curated headlines link to their original publishers.